Find Academic Supervisors

Vikas SrivastavaView profile

Associate Professor

• Solid Mechanics
• Continuum Biomechanics
• Cell Mechanics
• +7 more

Dr. Vikas Srivastava is an Associate Professor of Engineering and Director of the Graduate Program in Biomedical Engineering at Brown University's School of Engineering. His research focuses on solid mechanics, continuum biomechanics, and cell mechanics, with applications in materials under extreme environments and biomedical science. He leads the Srivastava Lab for Solid Mechanics and Biomechanics, which integrates computational models with experimental techniques to address interdisciplinary challenges. Dr. Srivastava holds a Ph.D. in Mechanical Engineering from MIT (2010) and previously held senior roles at ExxonMobil, including leadership in materials mechanics and deepwater drilling engineering. His academic career at Brown began in 2018, during which he has directed over 15 graduate students and secured notable funding. His research interests span mechanobiology, hydrogel-based drug delivery systems, AI-driven predictive modeling, and biomaterial innovations for cancer therapies. He has pioneered physics-informed neural networks for material characterization and developed novel hydrogels to enhance chemotherapy efficacy. Recent articles highlight advancements in polymer fracture modeling, machine learning for non-destructive evaluation, and predictive epidemiological modeling for pandemics. Dr. Srivastava has received the Dean’s Award in Bioengineering and was promoted to tenured Associate Professor in 2023. He actively mentors students through grants like the NSF Graduate Research Fellowship and leads initiatives in biomedical technology translation. The Srivastava Lab collaborates extensively across engineering, biology, and medicine to advance translational research in materials science and clinical applications.

Hong HanView profile

Assistant Professor

• Cancer Biology
• Gene Regulation
• RNA Splicing
• +5 more

Hong Han is an Assistant Professor in the Department of Biochemistry & Biomedical Sciences within McMaster University's Faculty of Health Sciences and a member of the Centre for Discovery in Cancer Research (CDCR). She holds a Canada Research Chair and leads the Han Lab, which focuses on cancer biology, RNA regulation, and innovative high-throughput technologies for therapeutic discovery. Dr. Han earned her Ph.D. from the University of Toronto (2010-2016) and has established herself as a leading researcher in glioblastoma and alternative splicing regulation. Her interdisciplinary research integrates cancer biology, RNA science, and multilayer gene regulation to uncover mechanisms underlying cancer progression and treatment resistance. Her laboratory pioneers integrated technological platforms for large-scale genetic/drug screening and ultra-high-throughput single-cell profiling. The research focuses on three main areas: alternative splicing regulation in cancer (particularly glioblastoma and prostate cancer), multilayer mechanisms of glioblastoma heterogeneity and microenvironment evolution, and multiplexed screening approaches for therapeutic discovery in treatment-resistant cancers. Analysis of Dr. Han's recent publications reveals a strong emphasis on single-cell technologies to characterize glioblastoma heterogeneity, minimal residual disease states, and tumor-immune interactions. Her work increasingly bridges basic RNA biology with translational applications, particularly in developing novel therapeutic strategies targeting splicing networks and immune evasion mechanisms. Canada Research Chair Dr. Han teaches Advanced Techniques in the Biomedical Sciences (BIOCHEM 734). Her research program is supported by multiple funding sources, as evidenced by her extensive publication record in high-impact journals including Nature, Cell, Molecular Cell, and Nature Communications. She employs a comprehensive approach combining in vitro, in vivo, and patient cohort studies with cutting-edge genomic technologies. The Han Lab has developed innovative multiplexed screening platforms that enable simultaneous interrogation of thousands of conditions, ranging from CAR-T cells to small molecule therapeutics. This approach accelerates the discovery of novel cancer targets and therapeutic strategies for treatment-resistant cancers.

Kristina SchoonjansView profile

Associate Professor

• Bile acid signaling
• Nutrient sensing
• Intermediary metabolism
• +11 more

Kristina Schoonjans is an Associate Professor at EPFL’s School of Life Sciences, where she leads the Laboratory of Metabolic Signaling (UPSCHOONJANS). Her research focuses on the molecular mechanisms of bile acid signaling, nutrient sensing, and intermediary metabolism, particularly in the context of metabolic disorders such as obesity, fatty liver disease, and cancer. She investigates how the liver-gut-brain axis integrates metabolic signals through nuclear receptors and mitochondrial dynamics. Her research interests include: Bile acid signaling and its role as a hormonal regulator Nutrient and metabolite sensing in energy homeostasis Intermediary metabolism and metabolic disorders Role of nuclear receptors (e.g., TGR5, LRH-1) in liver, gut, and adipose tissue Mitochondrial dynamics and fission in metabolic regulation Organoid models for studying liver and intestinal metabolism Systems genetics using BXD mouse populations The most recent articles highlight a strong focus on bile acid signaling, particularly through TGR5 and LRH-1, in regulating metabolic health. Themes include the conversion of white fat to beige fat (beiging), hepatic tumorigenesis, mitochondrial fission, and the use of organoid and genetically engineered mouse models. There is a consistent emphasis on translational applications for obesity, fatty liver disease, and cancer. Scientific honors include: Windaus Prize from the Dr. Falk Foundation (2010, shared with Johan Auwerx) for the discovery of the signaling/endocrine function of bile acids Prof. Schoonjans actively supervises PhD students and has advised numerous doctoral candidates who have since completed their theses. Her lab is supported by multiple grants from Swiss and international funding agencies, including the Swiss National Science Foundation, EPFL, CONACYT, and the Foundation for Health and Education. She teaches in several doctoral programs at EPFL, including Life Sciences Engineering, and contributes to education through the SSV and EDBB/EDCB/EDMS-ENS programs. The Schoonjans Lab brings together scientists, doctoral assistants, and technicians working on projects related to metabolic signaling. The team uses advanced techniques such as genetically modified mouse models, organoid cultures, and multi-omics (metabolomics, proteomics, transcriptomics) to study the liver-gut and brain-liver axes. The lab has a strong track record of high-impact publications and collaborations with institutions worldwide.

Chengzhong (Michael) YuView profile

Research Professor

• Nanotechnology
• Materials Science
• Drug Delivery
• +5 more

Professor Chengzhong (Michael) Yu is a Research Professor at the Australian Institute for Bioengineering and Nanotechnology (AIBN), University of Queensland. His research focuses on functional nanomaterials for healthcare, energy, and environmental applications. He holds over 400 publications with 36,000+ citations and has received prestigious awards like the NHMRC Leadership Fellowship and ARC Future Fellowship. Education: PhD in Chemistry from Fudan University. Research Interests: Silica-based nanoparticles for drug/gene delivery, energy storage materials (e.g., aluminum-ion batteries), sustainable catalysis, and nano-pesticides for agriculture. His group develops biomaterials for cancer therapy, immunotherapy, and mRNA vaccine platforms. Recent Trends in Publications: Focused on advancing nanocarrier systems for therapeutics, electrocatalytic H₂O₂ synthesis from seawater, and sustainable energy solutions. Collaborates with industry partners like N4 Pharma and Baosteel for translational applications. Awards & Grants: Multiple ARC Discovery/Linkage grants, NHMRC funding, and industry partnerships totaling millions. Notable projects include mRNA delivery platforms and rechargeable aluminum-ion batteries. Supervision & Labs: Mentors over 20 PhD/Master’s students. Leads the Yu Group, collaborating on projects like ‘Designer Nanoparticles for mRNA Factories’ and ‘Nanotechnology for Flystrike Control in Livestock’.

• Hematopathology
• Molecular Diagnostics
• Flow Cytometry
• +7 more

Alexa Siddon, MD, is an Assistant Professor in the Department of Laboratory Medicine at Yale School of Medicine, with secondary appointments in Pathology. She serves as Hematopathology Fellowship Director, Director of the Molecular Diagnostics Laboratory, Director of Flow Cytometry, and Associate Director of the Hematology Laboratory. She is also affiliated with the Yale Cancer Center, Clinical Flow Cytometry Laboratory, and the Hematopathology Laboratory at the Veteran Affairs Connecticut Healthcare System. Dr. Siddon's research focuses on hematopathology, particularly myeloid malignancies, acute leukemias, and post-transplant monitoring. Her work integrates molecular diagnostics, flow cytometry, and genomic analysis to improve patient diagnosis and outcomes. She has co-authored over 10 peer-reviewed articles in recent years, frequently collaborating with leading hematologists and pathologists such as Christopher Tormey, Henry Rinder, and Rory Shallis. Her publications reveal a strong trend in translational research, emphasizing the clinical implications of genetic mutations (e.g., TP53, NPM1, IDH1/2), chimerism testing post-transplant, and immunophenotypic characterization of hematologic malignancies. The research spans disciplines including oncology, molecular biology, immunology, and clinical pathology, with a clear focus on precision diagnostics and prognostic modeling. Scientific Awards: ASCP Distinguished Educator Award Paul J. Strandjord Young Investigator Award Donald H. Buchholz Research Prize Dr. Siddon is actively involved in medical education, directing fellowship programs and mentoring trainees. She has no reported grants listed in the text, but her leadership in diagnostic laboratories and active publication record suggest ongoing research funding. She is not part-time, not retired, and remains a current, active faculty member. She is affiliated with multiple research entities including the Cancer Immunology Center, Center for Biomedical Data Science, and the Yale Cancer Center, contributing to interdisciplinary teams focused on hematologic malignancies and diagnostic innovation.

• Oncology
• Sarcoma Research
• Precision Medicine
• +3 more

Pedro A Hermida de Viveiros, MD serves as an Assistant Professor in the Department of Medicine, Division of Hematology and Oncology at Northwestern University's Feinberg School of Medicine. His clinical practice focuses on solid tumor oncology with specialized expertise in sarcomas and precision medicine approaches. His research interests center on clinical development of novel therapeutic strategies for sarcomas and gastrointestinal stromal tumors (GIST), emphasizing biomarker-driven treatments and molecularly targeted therapies. Key areas include IDH1-mutant chondrosarcoma management, neoadjuvant response assessment in sarcomas, and immunotherapy-radiotherapy combinations for metastatic disease. Analysis of his recent publications reveals a consistent focus on translating molecular targets into clinical applications, particularly through phase 1-3 trials of targeted agents like ivosidenib and IDRX-42. His work bridges radiological assessment, pathological response, and precision oncology frameworks for rare solid tumors. Professional engagements include active membership in major oncology societies: American Society of Clinical Oncology (ASCO) Connective Tissue Oncology Society (CTOS) Sociedade Brasileira de Oncologia Clínica (SBOC) European Society for Medical Oncology (ESMO) He currently leads four active clinical trials through the Robert H. Lurie Comprehensive Cancer Center, including the CHONQUER phase 3 study of ivosidenib for IDH1-mutant chondrosarcoma and first-in-human trials of novel agents for advanced solid tumors and GIST. His work integrates translational research with clinical trial design to advance personalized treatment paradigms.

Mirko TrajkovskiView profile

Professor

• Metabolic Diseases
• Obesity
• Insulin Resistance
• +5 more

Professor Mirko Trajkovski leads the Laboratory of Metabolic Diseases at the Faculty of Medicine, University of Geneva. He completed his PhD at the International Max Planck School in Dresden (2005), followed by postdoctoral research at ETH Zurich, before establishing his lab at University College London (2012) and moving to Geneva (2013). His work focuses on adipose tissue plasticity , gut microbiota , and their roles in obesity , diabetes , and insulin resistance . Swiss National Science Foundation Professor (2014) ERC Starting Grant (2014) & Consolidator Grant (2019) Dr Walter Seipp Prize & Carl Gustav Carus Prize (2005) His lab investigates fat browning mechanisms , microbiota-host communication , and multi-tissue metabolic regulation using in vivo , in vitro , and human cohort approaches. Recent publications emphasize microbiome-based therapies , temperature effects on metabolism , and gut-bone-adipose crosstalk . Current advisees include PhD student Silas Kieser, with past members like Jing Xue, Salvatore Fabbiano, and Claire Chevalier contributing to immuno-metabolism and microbial engineering projects.

Caryl SortwellView profile

Professor

• Parkinson's Disease
• Neurotrophic Factors
• Alpha-Synuclein Pathology
• +4 more

Caryl E. Sortwell is a Professor of Translational Neuroscience and Edwin A. Brophy Endowed Chair in Central Nervous System Disorders at Michigan State University's College of Human Medicine. She leads the Sortwell Lab within the Neuroscience Program and Grand Rapids Research Center, focusing on Parkinson's disease (PD) therapeutics. Education : B.S. in Psychology/Pre-medicine (University of Illinois, 1987), Ph.D. in Anatomy and Cell Biology/Neurobiology (University of Illinois at Chicago, 1994) Positions : Assistant/Associate Professor at Rush University Medical Center (1997-2005), Associate Professor at University of Cincinnati (2005-2009), Professor at MSU College of Human Medicine (2009-present) Her research investigates alpha-synuclein pathology in PD using preformed fibril models to study neurodegeneration, neuroinflammation, and therapeutic interventions. She explores neurotrophic factors like BDNF, gene therapies targeting CaV1.3 channels, and deep brain stimulation mechanisms. Her work emphasizes precision medicine approaches to optimize treatment outcomes. Scientific contributions include methodological advancements in neurochemical sensing with diamond electrodes and viral vector delivery systems. Key collaborations include research with Dr. Joe Patterson on alpha-synuclein genetic consequences. Technical Expertise : Immunohistochemistry, stereotactic surgery, in vivo neurotoxicant models, protein analysis (Western blot/ELISA), droplet digital PCR, and neuroinflammatory profiling

Océane MartinView profile

Lecturer

• Microbiota
• Cancer Biology
• Clinical Microbiology
• +9 more

Océane Martin is a Lecturer in Clinical Microbiology at the University of Bordeaux, where she conducts her research at the Institute of Cellular Biochemistry and Genetics, a joint unit of CNRS and the university. Her work bridges clinical microbiology, oncology, and nutritional sciences. Research Interests: Océane Martin specializes in the role of the microbiota in cancer development, particularly focusing on: Links between processed meat consumption, nitrites/nitrates, and colorectal cancer. The role of pathogenic bacteria like Helicobacter pylori and Salmonella in gastric and colorectal cancers. The gut-brain axis in glioblastoma, including how the microbiota influences tumor progression and therapeutic resistance through the GLIOBIOTA project. Intratumoral microbiota in brain tumors and their functional implications. Publication Trends: Her recent publications reflect a strong focus on bacterial genotoxins, DNA damage responses, host immune modulation, and dietary factors in carcinogenesis. Her work integrates molecular microbiology with immunology and cancer biology, often using in vivo models to study host-pathogen dynamics. Scientific Contributions: Member of ANSES working group (2020–2022) on nitrite salts in food. Invited expert at the French National Assembly on nitrite-related health risks. Regular contributor to public science communication via The Conversation and national media. Advising and Grants: While no formal students are listed, her leadership in the GLIOBIOTA project suggests active mentorship and grant-funded research. Her involvement in national expert panels and interdisciplinary projects indicates sustained funding and collaborative research networks. Labs and Teams: She conducts research at the Institute of Cellular Biochemistry and Genetics (University of Bordeaux / CNRS), contributing to teams focused on infection biology, microbiota, and cancer. Her work aligns with translational research initiatives linking diet, microbiology, and oncology.

Anna Mathia KlawonnView profile

Associate Professor

• Neuroscience
• Neuroimmunology
• Affective Disorders
• +6 more

Anna Mathia Klawonn is an Associate Professor affiliated with three units at Aarhus University: the Danish Research Institute of Translational Neuroscience (DANDRITE), the Department of Biomedicine, and the Department of Molecular Biology and Genetics - Neurobiology. As a group leader at DANDRITE, she explores neural circuits and immune-to-brain signaling mechanisms regulating affective states through transgenic strategies and neurocircuitry techniques. Neuroscience Neuroimmunology Immune-to-Brain Signaling Affective Disorders Her research focuses on understanding how brain circuits and glial cells (microglia and astrocytes) contribute to affective states in both health and disease. Current projects investigate mechanisms in major depressive disorder and Parkinson's disease, emphasizing prostaglandin signaling, nicotinic receptor function, and striatal neuron modulation. Recent publications highlight her work in molecular neuroscience, neuropharmacology, and behavioral neuroscience. Key themes include cholinergic transmission in motivation, neuroimmune interactions in aversion, and reward/aversion circuitry. Her studies employ advanced neurocircuitry methods and transgenic models. In teaching, Klawonn is course responsible for the 3rd-semester Neuroscience course (10 ECTS) in the medical bachelor program. She actively engages in didactic development, frequently speaking about student motivation, flipped learning, and challenge-based learning. Klawonn leads the Klawonn Group at DANDRITE, with lab and office spaces in the Skou Building (Høegh-Guldbergs Gade 10, Aarhus C). Her work involves collaborations across neuroscience, neuroimmunology, and affective disease research.

Maartje BastingsView profile

Associate Professor

• Biomaterials Engineering
• DNA Nanotechnology
• Supramolecular Materials
• +5 more

Maartje Bastings is an Associate Professor at the École Polytechnique Fédérale de Lausanne (EPFL) , leading the Programmable Biomaterials Laboratory (PBL) within the School of Engineering (STI) . She holds additional affiliations with the Institute of Materials (IMX) , IBI-STI (Bioengineering), and supervises doctoral programs in Biotechnology and Biological Engineering ( EDBB-GE ) and Materials Science and Engineering ( EDMX-GE ). Her research focuses on DNA-based supramolecular materials engineered to achieve dynamic reciprocity —a two-way interaction between synthetic materials and biological systems. By leveraging DNA as a programmable scaffold, she investigates structural mechanics, valency control, and geometric constraints governing self-assembly and cell communication at bio-interfaces. Key applications include immune system modulation, diagnostics , and vaccine development . Analysis of her 15 most recent publications reveals a focus on multivalent interactions for T-cell activation, spatial patterning in immune signaling, and engineered coatings for DNA origami stability. Subfields span T cell receptor engineering , nanoscale protein dynamics , stimuli-responsive biomaterials , and bio-inspired therapeutic design . PhD Students: Chen Yuduo Hendrickx Pauline Bart M. Kononenko Artem Li Shujie Lou Yameng Meyer Pitt Narita Minako Rousseau Benjamin Bila Hale Caroprese Vincenzo Comberlato Alice Kurisinkal Eva Eugene Paloja Kaltrina Rodríguez Franco Hugo José Tekin Cem Wong Siu Ho Contact: maartje.bastings@epfl.ch

• Organic Chemistry
• Glycobiology
• Plant Biology
• +3 more

Fabian Pfrengle is a full Professor of Organic Chemistry at the Institute of Organic Chemistry , Department of Natural Sciences and Sustainable Resources , University of Natural Resources and Life Sciences Vienna (BOKU). He previously led research groups at the Max Planck Institute of Colloids and Interfaces (2013-2020) and worked at The Scripps Research Institute (2010-2013). Research Focus: His work bridges carbohydrate chemistry and plant biology , specializing in plant cell wall glycans and glycosyltransferases . He develops synthetic glycan arrays for enzyme characterization and investigates immune response triggering mechanisms in plants through oligosaccharide fragments . His projects include automated polysaccharide synthesis and liposome-based immune tolerance applications. Publication Trends: His 15 most recent articles emphasize chemical synthesis of sugar nucleotides , plant glycan arrays , and enzyme specificity analysis , reflecting his focus on carbohydrate engineering and plant immunity . Key subfields include UDP-sugar derivatization , Xylan structure-function relationships , and Glycosyltransferase profiling . Grants & Projects: Currently leads 5 major projects including Automated Algal Polysaccharide Synthesis (EU-funded, 2023-2028) and Synthetic Glycan Ligands for Plant Immune Receptors (FWF-funded, 2022-2026). His research also explores thrombocyte biology and Rhamnogalacturonan-II fragments with support from FWF and City of Vienna . Community Service: Serves on editorial boards ( Monatshefte für Chemie , 2021-present) and as reviewer for 12 journals including JACS Au , Nature Communications , and Angewandte Chemie . Member of professional societies: Gesellschaft Österreichischer Chemiker (2020), Deutscher Hochschulverband (2019), and Gesellschaft Deutscher Chemiker (2008).

Nicholas M. KanaanView profile

Professor

• Neurodegenerative Diseases
• Alzheimer's Disease
• Parkinson's Disease
• +6 more

Nicholas M. Kanaan is a Professor of Translational Neuroscience and holds the Maibach Smiley Professorship of Alzheimer's Research at Michigan State University's College of Human Medicine. He serves as Director of Advanced Microscopy and is faculty in both the MSU Neuroscience Program and the MSU BioMolecular Science Gateway. His research is centered at the Grand Rapids Research Center where he leads the Kanaan Laboratory. Dr. Kanaan received his B.S. in Neuroscience, Psychology, and Sociology from Central Michigan University in 2001, followed by a Ph.D. in Neurological Sciences from Rush University Medical Center in 2007. He completed postdoctoral training at Northwestern University from 2007-2010 under Dr. Lester Binder. His research focuses on neurodegenerative diseases, particularly Alzheimer's disease (AD) and Parkinson's disease (PD), with emphasis on tau protein pathology. The Kanaan Lab investigates mechanisms underlying degenerative diseases using a combination of in vitro and in vivo model systems. A major focus is understanding how disease-related alterations in tau cause neuronal dysfunction through disruption of axonal transport. His lab has identified a phosphatase-activating domain (PAD) in tau that inhibits anterograde fast axonal transport. Analysis of Dr. Kanaan's publication record reveals a consistent focus on tau protein biology, with recent work emphasizing iPSC models, CRISPR screening, tau proteostasis, and therapeutic interventions targeting tau phosphorylation and oligomerization. His research spans basic molecular mechanisms to translational applications, with increasing use of primate models and advanced screening technologies in recent years. Scientific Awards and Recognition: Maibach Smiley Alzheimer's Research Professor Maibach Smiley Professor of Alzheimer's Research Dr. Kanaan mentors numerous students and postdoctoral fellows in his laboratory, with research supported by multiple grants focused on understanding and treating neurodegenerative diseases. His lab employs a wide range of technical expertise including recombinant protein purification, cell culture, monoclonal antibody production, various microscopy techniques, and behavioral testing in rodent models. Outside the lab, Dr. Kanaan enjoys photography, woodworking, and fishing.

Kuo-Ching MeiView profile

Assistant Professor

• mRNA therapeutics
• lipid nanoparticles (LNPs)
• RNA delivery
• +7 more

Kuo-Ching Mei is an Assistant Professor of Molecular Pharmaceutics in the College of Pharmacy at the University of Utah. His laboratory pioneers lipid nanoparticle (LNP)-based gene delivery platforms that span cancer immunotherapy, immune tolerance induction, and programmable nanomedicine. Education B.Sc., Taipei Medical University Ph.D., University of London Dr. Mei’s research integrates molecular pharmaceutics, immunoengineering, and translational pharmaceutical sciences to advance precision immunotherapies. Core themes include mRNA-LNP systems for both immunostimulatory (anti-cancer vaccines) and immunomodulatory (tolerogenic) applications, the influence of immunometabolic cues (IFN-γ, amino-acid deprivation) on RNA translation, and the development of next-generation lipid chemistries for organ- and cell-specific delivery. Across his recent publications, a clear trend emerges toward refining LNP composition and architecture to enhance RNA delivery specificity, minimize toxicity, and modulate innate and adaptive immunity. Studies range from fundamental formulation science to pre-clinical evaluation in syngeneic tumor models and assessments of anti-vector immune responses. Research Support & Collaborations While specific grant numbers are not listed, the breadth and continuity of projects—from programmable lipid synthesis to high-throughput in vivo screening—indicate robust funding and active interdisciplinary collaborations within the University of Utah’s bioscience ecosystem. Laboratory & Team Dr. Mei leads a dynamic lab that employs chemical synthesis, formulation development, high-throughput screening, and integrated in vitro/in vivo disease models to translate discoveries into clinically viable RNA therapeutics and immunoengineering solutions.

Eduardo E. BenarrochView profile

Professor

• Neurodegenerative disorders
• Autonomic disorders
• Parkinson's disease
• +3 more

Eduardo E. Benarroch, M.D., is a Professor of Neurology and Consultant in the Department of Neurology at Mayo Clinic in Rochester, Minnesota. His research focuses on neurochemical mechanisms underlying neurodegenerative disorders such as multiple system atrophy (MSA) and Lewy body diseases, with emphasis on brainstem and hypothalamic neuronal groups controlling homeostasis. His work is supported by the MSA Coalition and has contributed to understanding autonomic, respiratory, and sleep symptom mechanisms in Parkinson's disease. Dr. Benarroch holds a D.Sci. in Physiology from Buenos Aires University and completed multiple fellowships including NIH Fogarty International Fellowship at Cornell University. He has held leadership roles including President of the American Autonomic Society and Co-Director of Mayo's Neuroscience Laboratory. His 286+ publications span neurochemical pathology, autonomic disorders, and clinical neurology. Awarded the AB Baker Lifetime Achievement Award in Neurologic Education, he has received repeated teaching honors including Mayo's Distinguished Educator Award. His professional memberships include American Academy of Neurology, Society for Neuroscience, and Sigma Xi. He has advised numerous trainees and contributed to consensus guidelines on dysphagia in neurodegenerative diseases.